C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

C4 Therapeutics, Inc.NASDAQ: CCCC

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 126.07M shares rose 78.0% year over year, ahead of the +38.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +78.0% holds above the trailing-twelve-month pace of +38.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
126.07M+8.0% QoQ
Last fiscal yearDec 2025
82.89M+19.5% YoY
LTMMar 2026
96.61M+38.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+78.0%——
1 year+19.5%——
3-year CAGR+19.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
82.89M USD
Year-over-year change
+19.5%
4-year CAGR
+15.8%

Weighted Avg Shares vs competitors

How CCCC compares with its peers on the latest reported figures

  • CCCC's LTM Mar 2026 weighted avg shares of 96.61M shares is the 3rd highest of the 9 companies compared; the peer median is 65.47M shares.
  • Its year-over-year change of +38.1% is the 3rd highest of 9, against a peer median of +24.8%.
  • Over three fiscal years its annual growth of +19.3% compares with a peer median of +16.0%.
CCCC Competitors Peer median
Weighted Avg Shares for CCCC and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202636.32M +0.4%+1.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
Peer median (excluding CCCC) 65.47M+24.8%+16.0%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.79M31.1M20.76M35.58M35.95M
Cost of Revenue007.74M07.98M
Gross Profit45.79M31.1M13.02M35.58M27.97M
Gross Margin100.0%100.0%62.7%100.0%77.8%
Research & Development94.67M117.84M117.71M110.64M104.24M
Selling, General & Admin33.25M42.79M42.08M42.12M36.2M
Operating Expenses127.92M160.63M152.05M155.2M132.46M
Depreciation & Amortization1.49M1.68M7.74M1.82M1.96M
EBITDA(80.26M)(124.28M)(122.1M)(103.37M)(102.91M)
EBITDA Margin-175.3%-399.7%-588.3%-290.5%-286.3%
Operating Income(82.13M)(129.53M)(139.03M)(119.61M)(104.49M)
Operating Margin-179.4%-416.6%-669.8%-336.1%-290.7%
Interest Income387K3.58M9.81M14.43M10.35M
Interest Expense2.15M2.22M1.37M00
Other Income / Expenses(1.76M)1.36M7.82M14.43M(384K)
Income Before Tax(83.89M)(128.18M)(131.21M)(105.19M)(104.87M)
Pre-Tax Margin-183.2%-412.2%-632.2%-295.6%-291.7%
Income Tax Expense001.28M131K121K
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Net Margin-183.2%-412.2%-638.3%-296.0%-292.1%
EPS (Basic)(1.82)(2.62)(2.67)(1.52)(1.27)
EPS (Diluted)(1.82)(2.62)(2.67)(1.52)(1.27)
Weighted Avg Shares46.04M48.86M49.64M69.37M82.89M
Weighted Avg Shares (Diluted)46.04M48.86M49.64M69.37M82.89M

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.